Pulse Biosciences shares rose 16% after the bioelectric medicine company issued product updates and said controlling stockholder and Chairman Robert W. Duggan is evaluating potential purchases of company stock.
The stock was recently at $8.47 and has more than quadrupled over the last 52 weeks.
Pulse has received all regulatory approvals for a planned catheter ablation feasibility study for its CellFX nsPFA Cardiac Catheter and said the first study procedures are scheduled for mid-December.
Additionally, Pulse said it anticipates filing a 510(k) submission with the Food and Drug Administration for its CellFX nsPFA Cardiac Clamp by the end of the January, and said a December filing is possible.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.